Axsome reports 57% revenue growth in Q1 2026 and FDA approval for AUVELITY in Alzheimer’s agitation

Axsome Therapeutics announced a 57% year-over-year increase in net product revenue to $191.2 million for Q1 2026, driven by strong sales of AUVELITY and SUNOSI. AUVELITY, approved by the FDA for agitation in Alzheimer’s disease, saw 59% revenue growth and is set for a full commercial launch in June 2026. The company also submitted an NDA for AXS-12 for narcolepsy and added a new drug candidate for schizophrenia and Tourette syndrome to its pipeline. Axsome plans to expand its sales force and advance multiple late-stage clinical trials, aiming to address significant unmet needs in CNS disorders.